{"id":26399,"date":"2026-03-17T19:01:15","date_gmt":"2026-03-17T18:01:15","guid":{"rendered":"https:\/\/lluita.org\/?p=26399"},"modified":"2026-03-17T19:01:15","modified_gmt":"2026-03-17T18:01:15","slug":"world-long-covid-day-three-research-projects-paving-the-way-towards-new-treatments","status":"publish","type":"post","link":"https:\/\/lluita.org\/en\/world-long-covid-day-three-research-projects-paving-the-way-towards-new-treatments\/","title":{"rendered":"World Long Covid Day: three research projects paving the way towards new treatments"},"content":{"rendered":"

Long Covid affects between 5% and 15% of people who have had a SARS\u2011CoV\u20112 infection. It is estimated that in Spain there are nearly 2 million people living with this syndrome,<\/strong> and more than 200,000 in Catalonia.<\/strong> However, only 15,000 people are formally diagnosed in Catalonia. This indicates that the condition is underdiagnosed, likely due to the nonspecific nature of its symptoms \u2014which can be mistaken for those of other health problems\u2014 as well as the absence of a diagnostic test capable of confirming the presence of the disease.<\/p>\n

\n

For this reason, on the occasion of World Long Covid Day, 15 March, the Fundaci\u00f3 Lluita contra les Infeccions wishes to highlight three key projects that are advancing the understanding and treatment of this condition: Thalassa, SuperCAP and COCOS.<\/strong> Together, they position us as a leading centre in clinical research into this illness and in supporting people affected by it.<\/p>\n<\/div>\n

\n

Thalassa: a pioneering clinical trial with plitidepsin<\/strong><\/h3>\n

Thalassa<\/a> is a phase II clinical trial led by the Foundation and the biopharmaceutical company PharmaMar to evaluate the safety and efficacy of plitidepsin<\/strong>, a marine\u2011derived active compound that induces apoptosis in affected cells, as a treatment for long Covid. The trial includes 90 participants,<\/strong> distributed between the active treatment and placebo arms, and has already surpassed half of its planned recruitment.<\/strong> To take part, people from across Spain travel weekly to the Foundation,<\/strong> located at the Hospital Germans Trias i Pujol in Badalona. This effort reflects both the lack of therapeutic alternatives and the strong clinical interest generated by the project.<\/p>\n<\/div>\n

\n

SuperCAP: digital technology to improve quality of life<\/strong><\/h3>\n

The SuperCAP<\/a> project aims to improve the quality of life of people affected by long Covid, focusing particularly on two of the most frequent symptoms: fatigue and cognitive difficulties.<\/p>\n

The project centres on evaluating the effectiveness of a personalised digital tool integrated into the eSalut platform, which combines:<\/p>\n